Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is considered as a remarkable anti-cancer therapeutic as it has the ability to selectively kill tumor cells, but not normal cells [1]. This evidence concerns the gene TNFSF10 and cancer.